CPCSEA registered, IVC barrier-maintained animal facility supporting safety pharmacology, PK/PD bioanalysis, acute/chronic toxicology, and disease efficacy models.
Oral, dermal, and intravenous single-dose acute toxicity testing per OECD Guidelines (420, 423, 425).
28-day repeated dose oral toxicity profiling evaluating target organ histopathology and clinical chemistry (OECD 407).
90-day to 180-day long-term safety evaluation for chronic systemic exposure and IND filing packages.
Single and multiple dose plasma kinetic profiling (Cmax, Tmax, AUC, t1/2, clearance) via LC-MS/MS.
Target engagement, physiological biomarker response, and dose-dependent therapeutic efficacy in-vivo.
Absolute and relative oral bioavailability (%F) comparison across formulation candidates.
Organ tissue accumulation profiling of radiolabeled or fluorescently tagged drug carrier nanoparticles.
Validated rodent disease models for pharmacology screening across metabolic, inflammatory, and oncological therapeutic areas.
Excision, incision, and burn wound models assessing tensile strength, hydroxyproline levels, and re-epithelialization rate.
Carrageenan-induced paw edema and cotton pellet granuloma models for anti-inflammatory drug screening.
STZ-induced diabetic models, oral glucose tolerance test (OGTT), and fasting blood glucose profiling.
Subcutaneous tumor xenograft mouse models monitoring tumor volume regression, survival, and biomarker modulation.
Subcutaneous, intramuscular, and bone tissue implantation safety per ISO 10993-6.
Long-term in-vivo biostability, biodegradation rate, and functional biocompatibility evaluation of novel medical polymers and scaffolds.
